OPDYTA 100MG

Description

Opdyta 100mg is a checkpoint inhibitor and a type of immunotherapy which helps make cancer cells more vulnerable to attack by your body’s own immune system

An antibody which encourages the tumor-killing effects of T cells (white blood cells that help your body fight disease)

Opdyta 100mg is prescription drug which is used under supervision of doctor

Indication

Opdyta 100mg is used for the treatment of patients having Melanoma 

Opdyta 100mg is used for the treatment of patients having Non-Small Cell Lung Cancer 

Opdyta 100mg is used for the treatment of patients having Kidney (Renal Cell) Cancer 

Mechanism of action

Nivolumab stops the activity of a molecule knowns as PD-1, a protein which prohibits T cells from identify and attacking inflamed tissues and cancer cells. PD-1 can deceit your immune system into overlooking melanoma cells as normal cells.

Nivolumab prompt your immune system’s response to melanoma by inhibiting the PD-1 protein on T cells.

Nivolumab stimulate T cells so that they can attack melanoma cells anywhere in your body. 

ADME Properties

The time to peak plasma concentration is between 1-4 hours

Volume of distribution is reported to be 8L

There is no information regarding the plasma protein bounding

Half-life elimination of Opdyta is 26.7 days.

Dosage and administration

Opdyta recommended dosage for unresectable or metastatic melanoma

As single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity

Concomitant use with ipilimumab. The prescribed dose of Opdyta is 1mg/kg administrated as an intravenous infusion over 30 minutes, followed by ipilimumab 3mg/kg given as IV over 90 minutes on the same day. Duration 3 weeks of max 4 doses, after completing combination dose continue the single agent treatment

For adjuvant treatment of melanoma: As single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity for up to 1 year.

For Non-small cell lung cancer: As single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity.

For small cell lung cancer; As single agent is either 240mg every 2 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity for up to 1 year.

For renal cell carcinoma: As single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity.

With ipilimumab

Opdyta of 3mg/kg administrated as IV infusion over 30 minutes and followed by 1mg/kg administrated as IV infusion over 30minutes on the same day. Duration 3 weeks of max 4 doses, after completing combination dose continue the single agent treatment.

Side effects

Common side effects of Opdyta 100mg

Fatigue

Lymphocytopenia (Low White Blood Cells)

Low Sodium

Shortness of breath

Musculoskeletal Pain

Decreased Appetite

Cough

Less common side effects Opdyta 100mg

Constipation

Increased serum creatinine

Colitis

Low potassium

Low magnesium

High calcium

Vomiting

Weakness

Diarrhea

High potassium

Low calcium

Swelling

Fever

Rash

Abdominal pain

Increased serum AST

Thrombocytopenia

Increased serum alkaline phosphatase

Chest pain

Weight loss

Drug interaction

No formal pharmacokinetic drug interaction studies

Precautions

While using Opdyta 100mg, Immune-mediated hepatitis observed in clinical trials; check for difference in liver function; withhold for moderate and permanently stop for severe or life-threatening transaminase or total bilirubin elevation

While using Opdyta 100mg Immune-mediated pneumonitis may appear to the patients; withhold for moderate and permanently discontinue for serious or life-threatening pneumonitis

While using Opdyta 100mg Other clinically significant and possible fatal immune-mediated side effects (eg, myocarditis, rhabdomyolysis, myositis, uveitis, iritis, pancreatitis) can appear after therapy discontinuation 

While using Opdyta 100mg Serious infusion reactions resulted (rare, <1%); stop if severe or life-threatening; break or slow rate of infusion in patients with mild or moderate infusion reactions

While using Opdyta 100mg Immune-mediated colitis resulted; withhold for moderate or serious and permanently stop for life-threatening colitis

While using Opdyta 100mg Immune-mediated hepatitis seen in clinical trials; check for liver function changes; withhold for limited and permanently stop for serious or life-threatening transaminase or total bilirubin elevation.

While using Opdyta 100mg It may cause fetal harm; advise of possible risk to a foetus and use of effective contraception

Pregnancy

The drug-associated risk has no data available. Advise pregnant women of the potential risk to a foetus. Since the effects of Opdyta 100mg are expected to be greater during the second and third trimesters of pregnancy.

Lactation

Opdyta 100mg Excretion in human breast milk is not known; advise women to discontinue breastfeeding during treatment

Storage

Store at under refrigeration at 2⁰C to 8⁰C

Missed dose

If you failed a dose take it as soon as possible, if time reach for next dose, then skip missed dose and continue regular schedule. Avoid taking two doses at a time. Avoid taking missed dose within 12hrs of the next dose.